BTIG analyst Sean Lavin maintained a Hold rating on Transenterix Inc (NYSE: TRXC) yesterday. The company’s shares closed yesterday at $4.76.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 14.5% and a 62.3% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Helius Medical Technologies, Tactile Systems Technology, and Obalon Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Transenterix Inc with a $5.17 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.04 and a one-year low of $0.67. Currently, Transenterix Inc has an average volume of 7.4M.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is neutral on the stock. Last month, Todd Pope, the President & CEO of TRXC bought 61,172 shares for a total of $21,410.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransEnterix, Inc. operates as a development stage medical device company. It focuses on research, development and sale of medical device robotics to improve minimally invasive surgery.
Read More on TRXC:
